

Ina Oehme

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2790869/publications.pdf>

Version: 2024-02-01

45
papers

7,681
citations

331259

21
h-index

377514

34
g-index

47
all docs

47
docs citations

47
times ranked

17601
citing authors

#	ARTICLE	IF	CITATIONS
1	iTReX: Interactive exploration of mono- and combination therapy dose response profiling data. Pharmacological Research, 2022, 175, 105996.	3.1	11
2	Functional Therapeutic Target Validation Using Pediatric Zebrafish Xenograft Models. Cancers, 2022, 14, 849.	1.7	13
3	Identification of histone deacetylase 10 (HDAC10) inhibitors that modulate autophagy in transformed cells. European Journal of Medicinal Chemistry, 2022, 234, 114272.	2.6	15
4	First Fluorescent Acetylspermidine Deacetylation Assay for HDAC10 Identifies Selective Inhibitors with Cellular Target Engagement**. ChemBioChem, 2022, 23, .	1.3	9
5	MODL-15. High-throughput combination drug screening identifies synergism between retinoic acid treatment and BCL-XL-inhibition in MYC(N)-driven medulloblastoma and neuroblastoma models. Neuro-Oncology, 2022, 24, i171-i172.	0.6	1
6	MODL-04. Drug screening in Disorders with Abnormal DNA Damage Response/Repair (DADDR) and in vivo validation. Neuro-Oncology, 2022, 24, i168-i169.	0.6	0
7	LGG-18. Inhibition of Bcl-xL targets the senescent compartment of pilocytic astrocytoma. Neuro-Oncology, 2022, 24, i91-i92.	0.6	0
8	LGG-25. The first-in-class ERK inhibitor ulixertinib (BVD-523) shows activity in MAPK-driven pediatric low-grade glioma models as single agent and in combination with MEK inhibitors or senolytics. Neuro-Oncology, 2022, 24, i93-i93.	0.6	0
9	DDEL-01. The role of key pharmacodynamic and pharmacokinetic parameters in drug response prediction of pediatric tumors in the precision oncology study INFORM. Neuro-Oncology, 2022, 24, i33-i34.	0.6	0
10	Multimomics analysis of pediatric solid tumors within the INFORM precision oncology study: From functional drug profiling to biomarker identification.. Journal of Clinical Oncology, 2022, 40, 10036-10036.	0.8	0
11	Design, Synthesis and Biological Characterization of Histone Deacetylase 8 (HDAC8) Proteolysis Targeting Chimeras (PROTACs) with Anti-Neuroblastoma Activity. International Journal of Molecular Sciences, 2022, 23, 7535.	1.8	15
12	Broad-Spectrum HDAC Inhibitors Promote Autophagy through FOXO Transcription Factors in Neuroblastoma. Cells, 2021, 10, 1001.	1.8	17
13	EMBR-01. CLASS I HDAC INHIBITORS AND PLK1 INHIBITORS SYNERGIZE IN MYC-AMPLIFIED MEDULLOBLASTOMA. Neuro-Oncology, 2021, 23, i5-i5.	0.6	0
14	EMBR-11. SYNERGISTIC DRUG COMBINATIONS FOR THE TREATMENT OF MYC AMPLIFIED GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology, 2021, 23, i7-i8.	0.6	0
15	TMOD-04. IMAGE-BASED DRUG RESPONSE PROFILING FROM PEDIATRIC TUMOR CELL SPHEROIDS USING PATIENT-BY-PATIENT DEEP TRANSFER LEARNING. Neuro-Oncology, 2021, 23, i36-i36.	0.6	0
16	LGG-11. BH3-MIMETICS TARGETING BCL-XL SELECTIVELY IMPACT THE SENESCENT COMPARTMENT OF PILOCYTIC ASTROCYTOMA. Neuro-Oncology, 2021, 23, i33-i34.	0.6	0
17	Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma. Cancers, 2021, 13, 4476.	1.7	8
18	Rapid In Vivo Validation of HDAC Inhibitor-Based Treatments in Neuroblastoma Zebrafish Xenografts. Pharmaceuticals, 2020, 13, 345.	1.7	19

#	ARTICLE	IF	CITATIONS
19	Design and Synthesis of Dihydroxamic Acids as HDAC6/8/10 Inhibitors. <i>ChemMedChem</i> , 2020, 15, 1163-1174.	1.6	21
20	MBRS-19. SYNERGISM OF HDAC AND PARP INHIBITORS IN MYC-DRIVEN GROUP 3 MEDULLOBLASTOMA CELLS. <i>Neuro-Oncology</i> , 2020, 22, iii401-iii401.	0.6	0
21	Synthesis and structure activity relationship of 1, 3-benzo-thiazine-2-thiones as selective HDAC8 inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2019, 184, 111756.	2.6	17
22	Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 4426-4443.	2.9	56
23	The enzyme activity of histone deacetylase 8 is modulated by a redox-switch. <i>Redox Biology</i> , 2019, 20, 60-67.	3.9	37
24	A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment. <i>Cell Death and Differentiation</i> , 2018, 25, 2053-2070.	5.0	22
25	Dual role of HDAC10 in lysosomal exocytosis and DNA repair promotes neuroblastoma chemoresistance. <i>Scientific Reports</i> , 2018, 8, 10039.	1.6	36
26	The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines. <i>Archives of Toxicology</i> , 2018, 92, 2649-2664.	1.9	28
27	DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats. <i>Nature Genetics</i> , 2017, 49, 1052-1060.	9.4	235
28	Three-dimensional tumor cell growth stimulates autophagic flux and recapitulates chemotherapy resistance. <i>Cell Death and Disease</i> , 2017, 8, e3013-e3013.	2.7	43
29	Structure-Based Design and Biological Characterization of Selective Histone Deacetylase 8 (HDAC8) Inhibitors with Anti-Neuroblastoma Activity. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 10188-10204.	2.9	56
30	Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing. <i>Oncotarget</i> , 2017, 8, 11460-11479.	0.8	43
31	Pediatric Targeted Therapy: Clinical Feasibility of Personalized Diagnostics in Children with Relapsed and Progressive Tumors. <i>Brain Pathology</i> , 2016, 26, 506-516.	2.1	14
32	Targeting histone deacetylase 8 as a therapeutic approach to cancer and neurodegenerative diseases. <i>Future Medicinal Chemistry</i> , 2016, 8, 1609-1634.	1.1	79
33	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	4.3	4,701
34	Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 1545-1555.	2.9	90
35	Inhibition of Histone Deacetylases Permits Lipopolysaccharide-Mediated Secretion of Bioactive IL-1 β via a Caspase-1-Independent Mechanism. <i>Journal of Immunology</i> , 2015, 195, 5421-5431.	0.4	36
36	HDAC8: a multifaceted target for therapeutic interventions. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 481-492.	4.0	210

#	ARTICLE	IF	CITATIONS
37	Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma. Acta Neuropathologica Communications, 2015, 3, 22.	2.4	66
38	HDAC Family Members Intertwined in the Regulation of Autophagy: A Druggable Vulnerability in Aggressive Tumor Entities. Cells, 2015, 4, 135-168.	1.8	71
39	<i>GRHL1</i> Acts as Tumor Suppressor in Neuroblastoma and Is Negatively Regulated by MYCN and HDAC3. Cancer Research, 2014, 74, 2604-2616.	0.4	54
40	Histone deacetylase 10 promotes autophagy-mediated cell survival. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E2592-601.	3.3	168
41	Histone deacetylase 10-promoted autophagy as a druggable point of interference to improve the treatment response of advanced neuroblastomas. Autophagy, 2013, 9, 2163-2165.	4.3	22
42	HDAC5 and HDAC9 in Medulloblastoma: Novel Markers for Risk Stratification and Role in Tumor Cell Growth. Clinical Cancer Research, 2010, 16, 3240-3252.	3.2	175
43	Histone Deacetylase 8 in Neuroblastoma Tumorigenesis. Clinical Cancer Research, 2009, 15, 91-99.	3.2	335
44	HDAC family: What are the cancer relevant targets?. Cancer Letters, 2009, 277, 8-21.	3.2	893
45	Targeting of HDAC8 and investigational inhibitors in neuroblastoma. Expert Opinion on Investigational Drugs, 2009, 18, 1605-1617.	1.9	64